Sutro Biopharma Cash on Hand 2017-2022 | STRO

Sutro Biopharma cash on hand from 2017 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Sutro Biopharma Annual Cash on Hand
(Millions of US $)
2021 $198
2020 $368
2019 $118
2018 $204
2017 $22
2016 $48
Sutro Biopharma Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $209
2021-12-31 $198
2021-09-30 $230
2021-06-30 $259
2021-03-31 $251
2020-12-31 $368
2020-09-30 $281
2020-06-30 $250
2020-03-31 $115
2019-12-31 $118
2019-09-30 $125
2019-06-30 $153
2019-03-31 $171
2018-12-31 $204
2018-09-30 $123
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2016-12-31 $48
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.246B $0.062B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00